Señales en vivo de 002399.SZ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 may 2024 @ 03:04):

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally...

Stats
Volumen de hoy	17.45M
Volumen promedio	6.23M
Capitalización de mercado	12.98B
EPS	CNY0 ( 2024-04-28 )
Próxima fecha de ganancias	( CNY0 ) 2024-05-22
Last Dividend	CNY0 ( N/A )
Next Dividend	CNY0 ( N/A )
P/E	-22.15
ATR14	CNY0.0130 (0.13%)

Volumen Correlación

Largo: -0.50 (neutral)

Corto: 0.47 (neutral)

Signal:(38.076) Neutral

Shenzhen Hepalink Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shenzhen Hepalink Correlación - Moneda/Commodity

-0.57
( weak negative )

-0.16
( neutral )

0.00
( neutral )

-0.89
( strong negative )

-0.08
( neutral )

0.87
( strong )

Shenzhen Hepalink Finanzas

Annual	2023
Ingresos:	CNY5.42B
Beneficio Bruto:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2023
Ingresos:	CNY5.42B
Beneficio Bruto:	CNY1.68B (30.90 %)
EPS:	CNY-0.530

FY	2022
Ingresos:	CNY7.16B
Beneficio Bruto:	CNY2.33B (32.61 %)
EPS:	CNY0.500

FY	2021
Ingresos:	CNY6.37B
Beneficio Bruto:	CNY2.03B (31.94 %)
EPS:	CNY0.164

Financial Reports:

No articles found.

Shenzhen Hepalink

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.